10-Q: Revvity Reports Q2 Growth Amidst Segment Shifts

Revvity, Inc. announced its second-quarter fiscal year 2026 results, showcasing a 1% revenue increase driven by its Diagnostics segment, while navigating a slight decrease in its Life Sciences segment.

Summary

• Total revenue for the second quarter of fiscal year 2026 was $729.7 million, a 1% increase from $720.3 million in the prior year period.
• The Diagnostics segment revenue grew by 5% to $371.0 million, primarily due to an increase in Reproductive Health business.
• The Life Sciences segment revenue decreased by 2% to $358.7 million, attributed to a decline in Software revenue.
• Consolidated gross margins improved to 57.1% from 54.5% in the prior year quarter, largely due to tariff refunds and a favorable product mix.
• Operating income from continuing operations was $89.3 million, a slight decrease from $90.8 million in the prior year quarter, impacted by restructuring charges and digital investments.
• Net income for the quarter was $51.8 million, or $0.47 per diluted share, compared to $53.9 million, or $0.46 per diluted share, in the prior year quarter.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, with revenue growth and improved gross margins offset by increased operating expenses and a decline in the Life Sciences segment.

Positives

• Total revenue increased by 1% to $729.7 million for the second quarter.
• Diagnostics segment revenue saw a robust 5% increase to $371.0 million, driven by the Reproductive Health business.
• Consolidated gross margins improved significantly by 260 basis points to 57.1%, aided by tariff refunds and a favorable product mix.
• The company received $16.2 million in tariff refunds, which positively impacted cost of revenue.
• Cash and cash equivalents increased to $1,022.9 million as of July 5, 2026.
• The company has $1.5 billion in borrowing capacity available under its senior unsecured revolving credit facility.

Negatives

• Life Sciences segment revenue decreased by 2% to $358.7 million, primarily due to a decline in Software revenue.
• Consolidated operating margins decreased from 12.6% to 12.2%, impacted by restructuring charges and digital investments.
• Selling, general and administrative expenses increased by 12% to $278.6 million, partly due to digital investments and restructuring charges.
• Restructuring and other costs increased significantly to $35.5 million from $11.2 million in the prior year quarter.
• Net income decreased slightly to $51.8 million from $53.9 million in the prior year quarter.
• Loss from discontinued operations was $1.7 million for the quarter.

Risks

• The company's growth and profitability are subject to global economic and political conditions, and operational disruptions.
• Failure to introduce new products in a timely manner could lead to market share loss and inability to achieve revenue growth targets.
• Acquisitions may not be successfully integrated or may not become profitable, potentially diluting earnings.
• Aggressive competition from numerous competitors could harm the business.
• Disruptions in third-party package delivery and import/export services could interfere with product shipment and increase costs.
• Supply chain disruptions from limited or single-source suppliers could adversely affect operations.
• Loss of key personnel could limit the ability to execute business strategy.
• Cybersecurity breaches or disruptions to IT systems could adversely affect the business.

Future Outlook

The company anticipates that its internal operations will generate sufficient cash to fund operating expenses, capital expenditures, acquisitions, interest payments, and dividends for the foreseeable future, including at least the next 12 months. The effective tax rate on continuing operations, before discrete items, is expected to be approximately 20% during fiscal year 2026.

Management Comments

• Revvity is revolutionizing whats possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
• Overall revenue in the second quarter of fiscal year 2026 was $729.7 million which increased by $9.4 million, or 1%, as compared to the second quarter of fiscal year 2025, reflecting an increase of $16.6 million, or 5%, in our Diagnostics segment revenue, and a decrease of $7.2 million, or 2%, in our Life Sciences segment revenue.
• Our consolidated gross margins increased 260 basis points from 54.5% to 57.1% in the second quarter of fiscal year 2026, as compared to the second quarter of fiscal year 2025, primarily due to tariff refunds and product mix shift.
• Our consolidated operating margins decreased from 12.6% to 12.2% in the second quarter of fiscal year 2026, as compared to the second quarter of fiscal year 2025, primarily due to restructuring charges and digital investments.

Industry Context

StockSavvy.ai notes that Revvity's performance reflects broader trends in the health science sector, with a strong showing in diagnostics (particularly reproductive health) while facing headwinds in software within the Life Sciences segment. The impact of tariff refunds highlights a specific, non-recurring positive factor influencing margins.

Legal Proceedings

• The company is subject to various claims, legal proceedings, and investigations arising in the ordinary course of business.
• Management believes the total cost of resolving these contingencies should not have a material adverse effect on the financial statements, but acknowledges uncertainties.
• The company is conducting environmental investigations and remedial actions at current and former locations and has been named a potentially responsible party for certain waste disposal sites.

Stakeholder Impact

• Shareholders may be impacted by the slight decrease in net income and the potential for future dividend adjustments.
• Employees may be impacted by restructuring charges and workforce reductions affecting approximately 5% of the workforce.
• Customers may benefit from ongoing product development and improved gross margins, but could be affected by supply chain or delivery disruptions.
• Creditors are subject to the company's debt levels and financial covenants, which are being managed within existing facilities.

Next Steps

• The company expects to close the divestiture of its Immunodiagnostics business in China by the end of 2027.
• The Board declared a quarterly dividend of $0.07 per share for the third quarter of fiscal year 2026, payable in November 2026.
• The company will continue to evaluate the impact of new accounting standards, including ASU 2025-10, ASU 2025-11, ASU 2025-06, and ASU 2024-03.
• The company will continue to monitor and manage market risks, including foreign currency exchange rates and interest rates.

Key Dates

Recommendation

The filing presents a mixed financial picture with modest revenue growth and improved gross margins, but also declining Life Sciences revenue, increased operating expenses due to restructuring, and a slight decrease in net income. While the Diagnostics segment is performing well and the company has strong liquidity, the overall performance is largely expected, with no significant positive catalysts for a buy recommendation. The risks outlined in the filing also warrant a cautious approach.

Keywords

health science solutions, diagnostics, life sciences, reproductive health, immunodiagnostics, software, revenue, operating income